Evidence map›Paper›PMID 23637645›Full record

ArticleTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2013

Impact of selection of cord blood units from the United States and swiss registries on the cost of banking operations.

Thomas Bart, Michael Boo, Snejana Balabanova, Yvonne Fischer, Grazia Nicoloso, Lydia Foeken, Machteld Oudshoorn, Jakob Passweg, Andre Tichelli, Vincent Kindler and 5 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05836974 (Performance Evaluation of the ex Utero Cord Blood Collection Technique), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05836974 nacompletednot on this mapstarted 2023, after this paper: background citation

Performance Evaluation of the ex Utero Cord Blood Collection Technique: Procedure, Quality and Results

TypeinterventionalSponsorFundacion DexeusRan2023 to 2024Enrolled133ConditionsUmbilical Cord BloodArmsEx-utero cord blood collection, In-utero cord blood collection
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 56 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Infectious Complications after Umbilical Cord-Blood Transplantation from Unrelated Donors.Mediterranean journal of hematology and infectious diseases · 2016
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Thomas BartTransfusion SRC Switzerland, Bern, Switzerland.
Michael Boo
Snejana Balabanova
Yvonne Fischer
Grazia Nicoloso
Lydia Foeken
Machteld Oudshoorn
Jakob Passweg
Andre Tichelli
Vincent Kindler
Joanne Kurtzberg
Thomas Price
Donna Regan
Elizabeth J Shpall
Rudolf Schwabe
National Marrow Donor Program · USSwiss Red Cross · CHUniversity of Basel · CHBloodworks Northwest · USUniversity of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOver the last 2 decades, cord blood (CB) has become an important source of blood stem cells. Clinical experience has shown that CB is a viable source for blood stem cells in the field of unrelated hematopoietic blood stem cell transplantation.

methodsStudies of CB units (CBUs) stored and ordered from the US (National Marrow Donor Program (NMDP) and Swiss (Swiss Blood Stem Cells (SBSQ)) CB registries were conducted to assess whether these CBUs met the needs of transplantation patients, as evidenced by units being selected for transplantation. These data were compared to international banking and selection data (Bone Marrow Donors Worldwide (BMDW), World Marrow Donor Association (WMDA)). Further analysis was conducted on whether current CB banking practices were economically viable given the units being selected from the registries for transplant. It should be mentioned that our analysis focused on usage, deliberately omitting any information about clinical outcomes of CB transplantation.

resultsA disproportionate number of units with high total nucleated cell (TNC) counts are selected, compared to the distribution of units by TNC available. Therefore, the decision to use a low threshold for banking purposes cannot be supported by economic analysis and may limit the economic viability of future public CB banking.

conclusionsWe suggest significantly raising the TNC level used to determine a bankable unit. A level of 125 × 10(7) TNCs, maybe even 150 × 10(7) TNCs, might be a viable banking threshold. This would improve the return on inventory investments while meeting transplantation needs based on current selection criteria.

Indexed as

Blood productsCD34+ cellsCollection efficiencyCord bloodCost-benefit analysisCost-effectiveness analysisCryopreservationHealth economicsHematopoietic cell transplantationHematopoietic stem cells

Identifiers

PMID23637645
PMCPMC3635979
OpenAlexW2052643123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.